Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00SIA
|
|||
| Former ID |
DIB016740
|
|||
| Drug Name |
ARQ-171
|
|||
| Synonyms |
ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
ArQule
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00398840) A Study of ARQ 171 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025396) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.